Report date: Mar 26, 2024 Conflict count: 356923 Publisher: Bentham Science Title count: 75 Conflict count: 333 ========================================================== Created: 2015-11-30 05:08:24.0 ConfID: 5071180 CauseID: 1387585786 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Musi, 2 ,2,119,2002,Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes DOI: 10.2174/1568008023340730(Journal) (5071180-N ) DOI: 10.2174/1568005310202020119(Journal) ========================================================== Created: 2015-11-30 05:08:24.0 ConfID: 5071181 CauseID: 1387585786 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Estlin, 2 ,2,141,2002,Novel Targets for Therapy in Paediatric Oncology DOI: 10.2174/1568008023340802(Journal) (5071181-N ) DOI: 10.2174/1568005310202020141(Journal) ========================================================== Created: 2015-11-30 05:08:24.0 ConfID: 5071182 CauseID: 1387585786 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Sugden, 2 ,2,151,2002,Therapeutic Potential of the Mammalian Pyruvate Dehydrogenase Kinases in the Prevention of Hyperglycaemia DOI: 10.2174/1568008023340785(Journal) (5071182-N ) DOI: 10.2174/1568005310202020151(Journal) ========================================================== Created: 2015-11-30 05:08:24.0 ConfID: 5071183 CauseID: 1387585786 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Krebs, 2 ,2,167,2002,Molecular Basis of Hyperparathyroidism and Potential Targets for Drug Development DOI: 10.2174/1568008023340686(Journal) (5071183-N ) DOI: 10.2174/1568005310202020167(Journal) ========================================================== Created: 2015-11-30 05:08:24.0 ConfID: 5071184 CauseID: 1387585786 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Ortiz, 2 ,2,181,2002,Apoptotic Cell Death in Renal Injury: The Rationale for Intervention DOI: 10.2174/1568008023340721(Journal) (5071184-N ) DOI: 10.2174/1568005310202020181(Journal) ========================================================== Created: 2015-11-30 05:08:35.0 ConfID: 5071185 CauseID: 1387585787 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Sorry, 2 ,1,13,2002,Hormone Mediation of Immune Responses in the Progression of Diabetes, Rheumatoid Arthritis and Periodontal Diseases DOI: 10.2174/1568008024606310(Journal) (5071185-N ) DOI: 10.2174/1568005310202010013(Journal) ========================================================== Created: 2015-11-30 05:08:35.0 ConfID: 5071186 CauseID: 1387585787 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Root, 2 ,1,27,2002,Clinical Pharmacology of Human Growth Hormone and its Secretagogues DOI: 10.2174/1568008024606293(Journal) (5071186-N ) DOI: 10.2174/1568005310202010027(Journal) ========================================================== Created: 2015-11-30 05:08:35.0 ConfID: 5071187 CauseID: 1387585787 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Galati, 2 ,1,53,2002,Cell Cycle Dysregulation During Hiv Infection: Perspectives of a Target Based Therapy DOI: 10.2174/1568008024606284(Journal) (5071187-N ) DOI: 10.2174/1568005310202010053(Journal) ========================================================== Created: 2015-11-30 05:08:35.0 ConfID: 5071188 CauseID: 1387585787 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Baron, 2 ,1,63,2002,Novel Peptides under Development for the Treatment of Type 1 and Type 2 Diabetes Mellitus DOI: 10.2174/1568008024606266(Journal) (5071188-N ) DOI: 10.2174/1568005310202010063(Journal) ========================================================== Created: 2015-11-30 05:08:35.0 ConfID: 5071189 CauseID: 1387585787 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Vancikova, 2 ,1,83,2002,Mucosal Immunity - Basic Principles, Ontogeny, Cystic Fibrosis and Mucosal Vaccination DOI: 10.2174/1568008024606301(Journal) (5071189-N ) DOI: 10.2174/1568005310202010083(Journal) ========================================================== Created: 2015-11-30 05:08:35.0 ConfID: 5071190 CauseID: 1387585787 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Rasgon, 2 ,1,97,2002,Common Treatment of Polycystic Ovarian Syndrome and Major Depressive Disorder: Case Report and Review DOI: 10.2174/1568008024606329(Journal) (5071190-N ) DOI: 10.2174/1568005310202010097(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071191 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Sarlis, 1 ,2,103,2001,Metastatic Thyroid Cancer Unresponsive to Conventional Therapies: Novel Management Approaches Through Translational Clinical Research DOI: 10.2174/1568008013341550(Journal) (5071191-N ) DOI: 10.2174/1568005310101020103(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071192 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Clark, 1 ,2,117,2001,Mechanisms of Interferon Mediated Anti-Viral Resistance DOI: 10.2174/1568008013341361(Journal) (5071192-N ) DOI: 10.2174/1568005310101020117(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071193 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Minoia, 1 ,2,131,2001,Metabolic Control Through L Calcium Channel, PKC and Opioid Receptors Modulation by an Association of Naloxone and Calcium Salts DOI: 10.2174/1568008013341505(Journal) (5071193-N ) DOI: 10.2174/1568005310101020131(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071194 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Theilade, 1 ,2,139,2001,G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling DOI: 10.2174/1568008013341352(Journal) (5071194-N ) DOI: 10.2174/1568005310101020139(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071195 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Lefebvre, 1 ,2,153,2001,Molecular Basis for Designing Selective Modulators of Retinoic Acid Receptor Transcriptional Activities DOI: 10.2174/1568008013341389(Journal) (5071195-N ) DOI: 10.2174/1568005310101020153(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071196 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Hornung, 1 ,2,165,2001,Photomedical Approaches for the Diagnosis and Treatment of Gynecologic Cancers DOI: 10.2174/1568008013341433(Journal) (5071196-N ) DOI: 10.2174/1568005310101020165(Journal) ========================================================== Created: 2015-11-30 05:08:51.0 ConfID: 5071197 CauseID: 1387585798 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: vancikova, 1 ,2,179,2001,Cytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A ReviewCytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A Review DOI: 10.2174/1568008013341334(Journal) (5071197-N ) DOI: 10.2174/1568005310101020179(Journal) ========================================================== Created: 2015-11-30 05:09:02.0 ConfID: 5071198 CauseID: 1387585799 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Xu, 3 ,1,23,2003,Unfolding the Pathophysiological Role of Bioactive Lysophospholipids DOI: 10.2174/1568008033340414(Journal) (5071198-N ) DOI: 10.2174/1568005310303010023(Journal) ========================================================== Created: 2015-11-30 05:09:02.0 ConfID: 5071199 CauseID: 1387585799 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Masuda, 3 ,1,43,2003,Vitamin D Analogs- Drug Design Based on Proteins Involved in Vitamin D Signal Transduction DOI: 10.2174/1568008033340315(Journal) (5071199-N ) DOI: 10.2174/1568005310303010043(Journal) ========================================================== Created: 2015-11-30 05:09:02.0 ConfID: 5071200 CauseID: 1387585799 OtherID: 241102043 JT: Current Drug Targets - Immune Endocrine & Metabolic Disorders MD: Portincasa, 3 ,1,67,2003,Pathobiology of Cholesterol Gallstone Disease: From Equilibrium Ternary Phase Diagram to Agents Preventing Cholesterol Crystallization and Stone Formation DOI: 10.2174/1568008033340397(Journal) (5071200-N ) DOI: 10.2174/1568005310303010067(Journal)